These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25393960)

  • 21. How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study.
    Lexchin J
    PLoS One; 2020; 15(11):e0240966. PubMed ID: 33137156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postmarket safety of drugs approved by Health Canada on the basis of clinical and surrogate outcomes: a cohort study.
    Lexchin J; Ahmed T
    CMAJ Open; 2015; 3(3):E286-91. PubMed ID: 26442227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accelerated approval of drugs: ethics versus efficacy.
    Chary KV; Pandian K
    Indian J Med Ethics; 2017; 2(4):244-247. PubMed ID: 28661403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.
    Lexchin J
    BMJ Open; 2017 Oct; 7(10):e018372. PubMed ID: 29061631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.
    Frank C; Himmelstein DU; Woolhandler S; Bor DH; Wolfe SM; Heymann O; Zallman L; Lasser KE
    Health Aff (Millwood); 2014 Aug; 33(8):1453-9. PubMed ID: 25092848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
    Kim J; Nair A; Keegan P; Beaver JA; Kluetz PG; Pazdur R; Chuk M; Blumenthal GM
    Oncologist; 2020 Apr; 25(4):348-354. PubMed ID: 32297444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug safety: withdrawn medications are only part of the picture.
    Rawson NS
    BMC Med; 2016 Feb; 14():28. PubMed ID: 26873482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Information about confirmatory studies required for new drugs conditionally approved by Health Canada: A cross-sectional study.
    Lexchin J
    PLoS One; 2022; 17(10):e0276672. PubMed ID: 36264963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014.
    Pinnow E; Amr S; Bentzen SM; Brajovic S; Hungerford L; St George DM; Dal Pan G
    Clin Pharmacol Ther; 2018 Aug; 104(2):390-400. PubMed ID: 29266187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-review deadlines and safety problems.
    Carpenter D; Zucker EJ; Avorn J
    N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.
    Botelho SF; Martins MA; Vieira LB; Reis AM
    J Clin Pharmacol; 2017 Apr; 57(4):493-499. PubMed ID: 27568487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Classification of nervous system withdrawn and approved drugs with ToxPrint features via machine learning strategies.
    Onay A; Onay M; Abul O
    Comput Methods Programs Biomed; 2017 Apr; 142():9-19. PubMed ID: 28325450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database.
    Mott K; Graham DJ; Toh S; Gagne JJ; Levenson M; Ma Y; Reichman ME
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1023-32. PubMed ID: 27146123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009.
    Qureshi ZP; Seoane-Vazquez E; Rodriguez-Monguio R; Stevenson KB; Szeinbach SL
    Pharmacoepidemiol Drug Saf; 2011 Jul; 20(7):772-7. PubMed ID: 21574210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative regulatory performance on introduction & withdrawal of drugs in India and EU/internationally.
    Kshirsagar NA; Bachhav SS
    Int J Risk Saf Med; 2013; 25(4):235-8. PubMed ID: 24305562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons.
    Mendes D; Alves C; Batel Marques F
    Expert Opin Drug Saf; 2016 Oct; 15(10):1301-12. PubMed ID: 27467204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy.
    Abraham J; Davis C
    Soc Sci Med; 2005 Sep; 61(5):881-92. PubMed ID: 15955393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost recovery by Health Canada and drug safety: a time-series analysis.
    Lexchin J
    CMAJ Open; 2018; 6(4):E471-E477. PubMed ID: 30337472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-induced ocular adverse reactions: review of the safety alerts issued during the last decade.
    Penedones A; Mendes D; Alves C; Marques FB
    J Ocul Pharmacol Ther; 2015 Jun; 31(5):258-68. PubMed ID: 25871404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.